Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Free Cash Flow (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Free Cash Flow for 12 consecutive years, with -$15.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 25.67% year-over-year to -$15.4 million, compared with a TTM value of -$72.4 million through Sep 2025, up 17.8%, and an annual FY2024 reading of -$86.5 million, down 54.23% over the prior year.
  • Free Cash Flow was -$15.4 million for Q3 2025 at CytomX Therapeutics, up from -$15.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $9.3 million in Q1 2023 and bottomed at -$42.0 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$22.4 million, with a median of -$21.5 million recorded in 2023.
  • Peak annual rise in Free Cash Flow hit 122.12% in 2023, while the deepest fall reached 13599.37% in 2023.
  • Year by year, Free Cash Flow stood at -$29.9 million in 2021, then soared by 100.53% to $159000.0 in 2022, then plummeted by 13599.37% to -$21.5 million in 2023, then rose by 6.88% to -$20.0 million in 2024, then rose by 22.85% to -$15.4 million in 2025.
  • Business Quant data shows Free Cash Flow for CTMX at -$15.4 million in Q3 2025, -$15.8 million in Q2 2025, and -$21.2 million in Q1 2025.